BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies

Sponsor
Principia Biopharma

Protocol Number
PRN1008-010:

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor

Type of Cancer
Hematological Malignancies

Sponsor
Incyte

Protocol Number
INCB 50465-204

To Learn More Call
201-510-0910

A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
201-510-0910

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura

Type of Cancer
Hematological Malignancies